TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression
Publication
, Conference
Secord, AA; Lewin, S; Method, M; Murphy, C
Published in: E-Posters (Trials In Progress)
December 2022
Duke Scholars
Published In
E-Posters (Trials In Progress)
DOI
Publication Date
December 2022
Start / End Page
A232 / A233
Publisher
BMJ Publishing Group Ltd
Conference Name
IGCS 2022 Annual Meeting Abstracts
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis
Citation
APA
Chicago
ICMJE
MLA
NLM
Secord, A. A., Lewin, S., Method, M., & Murphy, C. (2022). TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. In E-Posters (Trials In Progress) (pp. A232–A233). BMJ Publishing Group Ltd. https://doi.org/10.1136/ijgc-2022-igcs.528
Secord, Angeles Alvarez, Sharon Lewin, Michael Method, and Conleth Murphy. “TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression.” In E-Posters (Trials In Progress), A232–33. BMJ Publishing Group Ltd, 2022. https://doi.org/10.1136/ijgc-2022-igcs.528.
Secord AA, Lewin S, Method M, Murphy C. TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. In: E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A232–3.
Secord, Angeles Alvarez, et al. “TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression.” E-Posters (Trials In Progress), BMJ Publishing Group Ltd, 2022, pp. A232–33. Crossref, doi:10.1136/ijgc-2022-igcs.528.
Secord AA, Lewin S, Method M, Murphy C. TP019/#1556 PICCOLO: an open-label, single arm, phase 2 study of mirvetuximab soravtansine in recurrent platinum sensitive, high-grade epithelial ovarian cancers with high folate-alpha expression. E-Posters (Trials In Progress). BMJ Publishing Group Ltd; 2022. p. A232–A233.
Published In
E-Posters (Trials In Progress)
DOI
Publication Date
December 2022
Start / End Page
A232 / A233
Publisher
BMJ Publishing Group Ltd
Conference Name
IGCS 2022 Annual Meeting Abstracts
Related Subject Headings
- Oncology & Carcinogenesis
- 3211 Oncology and carcinogenesis
- 3202 Clinical sciences
- 1112 Oncology and Carcinogenesis